^
Association details:
| Biomarker: | THBS1 underexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Regimen: | CaT (carboplatin + paclitaxel) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Excerpt:
...patients (172 out of 187) received front-line carboplatin-paclitaxel regimen....Multivariate analysis demonstrated that high PRR13/low THBS1 expression was an independent factor for decreased PFS (hazards ratio: 1.94; 95% confidence interval (CI): 1.48–2.92; P=0.008) and OS (hazard ratio: 3.89; 95% CI: 2.16–6.87; P<0.001), whereas low TXN expression was correlated with decreased PFS (hazard ratio: 1.44; 95% CI: 1.05–2.84; P=0.043) and OS (hazard ratio: 2.38; 95% CI: 1.78–2.77; P=0.009).
DOI:
10.1038/tpj.2016.63
